Bicara Therapeutics Inc. (BCAX)
Nasdaq · Healthcare · Biotechnology
$17.29−1.93%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1B
- 52-week range
- $13.70 – $30.99
- 52-week change
- −2.97%
- EPS (trailing)
- −$3.08
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Net income
- −$138M
- Diluted EPS
- −$2.52
- Free cash flow
- −$107M
From the company’s annual report on SEC EDGAR.
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Headquarters: Boston, United States · 103 employees · bicara.com